• School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, 211198, P.R.China;
MA Aixia, Email: aixiama73@126.com
Export PDF Favorites Scan Get Citation

Objective To systematically review the efficacy and safety of capecitabine combined with irinotecan (CAPIRI) versus capecitabine combined with oxaliplatin (CAPOX) for patients with advanced/metastatic colorectal cancer.Methods PubMed, EMbase, The Cochrane Library, VIP, WanFang Data and CNKI databases were electronically searched to collect randomized controlled trials (RCTs) on CAPIRI versus CAPOX for patients with advanced/metastatic colorectal cancer from inception to August 2018. Two reviewers independently screened literature, extracted data, and assessed the risk of bias of included studies. Then, meta-analysis was performed by using RevMan 5.3 software.Results A total of 12 RCTs involving 1 049 patients were included. The results of meta-analysis showed that: there were no significant differences in complete response (CR), partial response (PR), stable disease (SD), progression disease (PD), overall respond rate (ORR), median progression-free survival (mPFS), and median overall survival (mOS) between two groups (P>0.05). However, CARIRI group was lower on the disease control rate (RR=0.93, 95%CI 0.86 to 1.00, P=0.04) than CAPOX group. Incidence of diarrhea was higher in CAPIRI group (RR=1.83, 95%CI 1.37 to 2.45, P<0.000 1). However, the incidence rate of peripheral neurotoxicity in CAPOX group was higher (RR=0.13, 95%CI 0.05 to 0.35, P<0.000 1). There were no significant differences between two groups in the incidence rates of nausea and vomiting, hand-foot syndrome, anemia, thrombocytopenia, leukocytopenia and alopecia (P>0.05).Conclusions Current evidence shows that two groups are equivalent in terms of curative effects. CAPIRI has a higher incidence rate of diarrhea, while CAPOX has a higher risk of peripheral neurotoxicity. Due to limited quality and quantity of the included studies, more high quality studies are required to verify above conclusions.

Citation: HE Yumei, TIAN Lei, MA Aixia. Efficacy and safety of capecitabine combined with irinotecan versus capecitabine combined with oxaliplatin in treatment of advanced/metastatic colorectal cancer: a systematic review. Chinese Journal of Evidence-Based Medicine, 2019, 19(3): 302-309. doi: 10.7507/1672-2531.201809002 Copy

  • Previous Article

    Efficacy of dendritic cells vaccines in colorectal cancer: a systematic review
  • Next Article

    The association between SIX6 gene rs10483727 polymorphism and primary open angle glaucoma: a meta-analysis and TSA